Is Sanofi India a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Sanofi India Ltd is a good quality company .

Is Sanofi India undervalued or overvalued?

The key valuation ratios of Sanofi India Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone .

What is Sanofi India share price return in the past 10 years?

Sanofi India Ltd share price has appreciated 10.3% annually (CAGR) over the past ten years.

Is Sanofi India a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Sanofi India Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.

Sanofi India Ltd - Stock Valuation and Financial Performance

Name: Sanofi India
Brand: Sanofi India

BSE: 500674 | NSE: SANOFI | Pharmaceuticals & Drugs | Small Cap

Place order

Sanofi India Share Price

₹8,155 -68.90 -0.84%
as on 23-Apr'24 15:40

10 Year X-Ray of Sanofi India:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Standalone Basis ^P Consolidated Basis

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Dec'13	Dec'14	Dec'15	Dec'16	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	TTM
ROCE % ⓘ	19.1%	15.5%	16.9%	17.3%	16.5%	17.8%	19.6%	22.4%	27.5%	30.2%	-
Value Creation Index ⓘ	0.4	0.2	0.3	0.3	0.2	0.3	0.5	0.7	1.0	1.2	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	1,809	1,977	2,193	2,367	2,464	2,771	3,071	2,902	2,957	2,770	2,851
Sales YoY Gr.	-	9.3%	10.9%	7.9%	4.1%	12.5%	10.8%	-5.5%	1.9%	-6.3%	-
Adj EPS ⓘ	105.4	95.4	114.3	131.3	139.9	163.5	197.9	220.9	259.2	229.4	261.9
YoY Gr.	-	-9.5%	19.8%	14.9%	6.6%	16.8%	21.1%	11.6%	17.4%	-11.5%	-
BVPS (₹) ⓘ	580.3	643.7	707.3	810.7	869.9	950.2	1,043.5	897.8	941.5	527.7	441
Adj Net Profit ⓘ	243	220	263	302	322	377	456	509	597	528	603
Cash Flow from Ops. ⓘ	273	265	213	322	435	374	412	611	559	399	-
Debt/CF from Ops. ⓘ	0	0	0	0	0	0	0	0	0	0	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	4.9%	2.4%	-3.4%	-6.3%
Adj EPS ⓘ	9%	10.4%	5%	-11.5%
BVPSⓘ	-1.1%	-9.5%	-20.3%	-44%
Share Price	10.3%	7.5%	2.5%	36.1%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Dec'13	Dec'14	Dec'15	Dec'16	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	TTM
Return on Equity % ⓘ	19	15.5	16.9	17.2	16.5	17.7	19.6	22.3	27.5	30.2	54.1
Op. Profit Mgn % ⓘ	22	17.3	21	22.6	21.9	22.6	21.7	24.7	25.8	25.4	28.2
Net Profit Mgn % ⓘ	13.4	11.1	12	12.8	13.1	13.6	14.9	17.5	20.2	19.1	21.2
Debt to Equity ⓘ	0	0	0	0	0	0	0	0	0	0	0
Working Cap Days ⓘ	122	151	149	156	287	379	386	419	436	446	73
Cash Conv. Cycle ⓘ	38	42	39	50	31	20	18	13	2	-3	29

Recent Performance Summary

Return on Equity has increased versus last 3 years average to 54.10%

Sales growth has been subdued in last 3 years -3.37%

Net Profit has been subdued in last 3 years 5.03%

Sales growth is not so good in last 4 quarters at 2.92%

Latest Financials - Sanofi India Ltd.

	Standalone	Consolidated
TTM EPS (₹)	261.9	261.8
TTM Sales (₹ Cr.)	2,851	2,851
BVPS (₹.) ⓘ	441	0
Reserves (₹ Cr.) ⓘ	993	992
P/BV ⓘ	18.47	0.00
PE ⓘ	31.09	31.11

From the Market
52 Week Low / High (₹)	5329.70 / 9370.35
All Time Low / High (₹)	235.05 / 9370.35
Market Cap (₹ Cr.)	18,754
Equity (₹ Cr.)	23
Face Value (₹)	10
Industry PE ⓘ	47.6

Management X-Ray of Sanofi India:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Valuation of Sanofi India

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

This is a premium feature, Please click here to check our solutions.

Key Ratios of Sanofi India

Standalone Basis Consolidated Basis

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Dec'14	Dec'15	Dec'16	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23
Sales	1,977	2,193	2,367	2,464	2,771	3,071	2,902	2,957	2,770	2,851
Operating Expenses ⓘ	1,639	1,734	1,832	1,926	2,148	2,405	2,189	2,194	2,067	2,048
Manufacturing Costs	221	217	121	120	144	142	114	88	84	89
Material Costs	870	912	1,065	1,004	1,146	1,347	1,254	1,307	1,190	1,201
Employee Cost	288	333	355	369	407	450	461	434	406	371
Other Costs ⓘ	259	272	290	434	451	466	361	366	387	388
Operating Profit ⓘ	339	459	535	537	623	665	713	762	703	803
Operating Profit Margin (%)	17.1%	20.9%	22.6%	21.8%	22.5%	21.7%	24.6%	25.8%	25.4%	28.2%
Other Income ⓘ	64	51	66	81	90	94	90	75	73	67
Interest ⓘ	0	0	2	1	1	0	2	2	2	2
Depreciation ⓘ	97	113	119	102	103	100	82	67	42	40
Exceptional Items ⓘ	67	84	0	0	0	-59	-42	489	132	18
Profit Before Tax ⓘ	373	481	480	515	610	600	677	1,258	864	846
Tax ⓘ	109	159	176	189	229	186	200	313	244	243
Profit After Tax	264	322	304	326	381	414	478	944	621	603
PAT Margin (%)	13.3%	14.7%	12.9%	13.2%	13.7%	13.5%	16.5%	31.9%	22.4%	21.2%
Adjusted EPS (₹)	114.5	139.8	132.3	141.7	165.5	180.1	207.7	410.6	269.8	262.3
Dividend Payout Ratio (%)	39%	47%	51%	50%	51%	194%	176%	119%	211%	64%

Balance Sheet

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Dec'14	Dec'15	Dec'16	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23
Equity and Liabilities
Shareholders Fund	1,486	1,627	1,865	2,001	2,186	2,400	2,065	2,166	1,214	947
Share Capital ⓘ	23	23	23	23	23	23	23	23	23	23
Reserves ⓘ	1,463	1,604	1,842	1,978	2,163	2,377	2,042	2,143	1,191	924
Minority Interest	0	0	0	0	0	0	0	0	0	0
Debt	0	0	0	0	0	0	0	0	0	0
Long Term Debt	0	0	0	0	0	0	0	0	0	0
Short Term Debt	0	0	0	0	0	0	0	0	0	0
Trade Payables	327	226	231	327	344	369	318	377	356	292
Others Liabilities ⓘ	415	552	446	1,996	2,240	2,471	2,710	3,013	3,258	3,464
Total Liabilities ⓘ	2,228	2,405	2,541	4,324	4,769	5,240	5,093	5,555	4,828	4,703
Fixed Assets
Gross Block	1,132	1,454	936	989	1,053	817	852	546	531	552
Accumulated Depreciation	484	577	119	220	321	318	388	212	225	237
Net Fixed Assetsⓘ	648	877	817	769	733	499	464	334	306	315
CWIP ⓘ	210	22	34	30	21	17	10	13	24	16
Investmentsⓘ	0	0	0	0	0	0	0	0	0	2
Inventories	478	479	493	416	483	470	368	392	408	664
Trade Receivables	115	144	145	195	158	224	148	143	129	132
Cash Equivalents	469	572	561	730	832	1,130	1,209	1,550	1,017	405
Others Assetsⓘ	307	310	492	2,184	2,542	2,901	2,895	3,123	2,945	3,170
Total Assets ⓘ	2,228	2,405	2,541	4,324	4,769	5,240	5,093	5,555	4,828	4,703

Cash Flow

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Dec'14	Dec'15	Dec'16	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23
Cash Flow From Operating Activity ⓘ	265	213	322	435	374	412	611	559	399	231
PBT ⓘ	306	397	480	515	610	600	677	1,258	864	846
Adjustment ⓘ	45	66	61	39	36	78	65	-482	-159	-25
Changes in Working Capital ⓘ	36	-112	-1	80	-28	-38	62	68	-46	-349
Tax Paid ⓘ	-123	-138	-218	-198	-244	-228	-193	-285	-261	-241
Cash Flow From Investing Activity ⓘ	61	36	-155	-79	-73	66	276	631	651	36
Capex	-18	-29	-69	-57	-57	-75	-41	-13	13	-10
Net Investments	0	-1	0	0	0	0	0	0	0	0
Others ⓘ	80	65	-86	-22	-16	141	317	643	638	46
Cash Flow From Financing Activityⓘ	-122	-147	-180	-188	-197	-183	-810	-849	-1,583	-878
Net Proceeds from Shares ⓘ	0	0	0	0	0	0	0	0	0	0
Net Proceeds from Borrowing ⓘ	0	0	0	0	0	0	0	0	0	0
Interest Paid ⓘ	0	0	0	0	0	0	-2	-2	-2	-2
Dividend Paid ⓘ	-121	-147	-150	-157	-164	-152	-804	-841	-1,573	-868
Others ⓘ	0	0	-31	-32	-34	-31	-5	-7	-8	-8
Net Cash Flow ⓘ	205	102	-13	168	104	295	78	341	-533	-612

Finance Ratio

Standalone Basis Consolidated Basis

PARTICULARS	Dec'14	Dec'15	Dec'16	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23
Ratios
ROE (%)	18.7	20.68	17.43	16.87	18.18	18.07	21.39	44.65	36.73	55.83
ROCE (%)	26.47	30.96	27.51	26.38	28.76	25.75	29.77	57.98	49.47	73.98
Asset Turnover Ratio	0.99	0.97	0.98	0.73	0.63	0.64	0.56	0.56	0.56	0.62
PAT to CFO Conversion(x)	1	0.66	1.06	1.33	0.98	1	1.28	0.59	0.64	0.38
Working Capital Days
Receivable Days	21	21	22	25	22	22	23	18	17	16
Inventory Days	74	78	73	67	57	54	53	47	50	66
Payable Days	108	111	78	101	107	97	100	97	112	98

Sanofi India Ltd Stock News

Sanofi India Ltd FAQs

What is the share price of Sanofi India?

Company share prices are keep on changing according to the market conditions. The closing price of Sanofi India on 23-Apr-2024 15:40 is ₹8,155.

What is the market cap of Sanofi India?

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 23-Apr-2024 15:40 the market cap of Sanofi India stood at ₹18,754.1.

What is the P/E ratio of Sanofi India?

The latest P/E ratio of Sanofi India as of 23-Apr-2024 15:40 is 31.09.

What is the P/B ratio of Sanofi India?

The latest P/B ratio of Sanofi India as of 23-Apr-2024 15:40 is 18.47.

What is the 52-week high and low of Sanofi India?

The 52-week high of Sanofi India is ₹9,370.4 and the 52-week low is ₹5,329.7.

What is the TTM revenue of Sanofi India?

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Sanofi India is ₹2,851 ( Cr.) .

About Sanofi India Ltd

Sanofi India is one of the entities through which Sanofi operates in India. It was incorporated in May 1956 under the name Hoechst Fedco Pharma Private Limited. Over the years, its name was changed to Hoechst Pharmaceuticals Private Limited, Hoechst India Limited, Hoechst Marion Roussel Limited and Aventis Pharma Limited. Sanofi, one of the world's leading healthcare companies, and its 100% subsidiary - Hoechst GmbH, are the major shareholders of Sanofi India Limited and together hold 60.4% of its paid-up share capital. The shares of Sanofi India Limited are quoted on the Bombay Stock Exchange and the National Stock Exchange. The company has two manufacturing sites in Ankleshwar and Goa. Sanofi India also manufactures its products through third party manufacturers. The different types of dosage forms include tablets, capsules (hard and soft), Eye/Ear drops, ampoules, vials, creams and ointments. These products are manufactured in accordance with the same quality standards as those prevalent at its own manufacturing sites for domestic consumption and for export to Russia, the Ukraine and other CIS countries.

Business area of the company

The company is dedicated to supporting people through their health challenges. It is a global biopharmaceutical company focused on human health. The company prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. The company stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.

Products

Pharmaceutical products (Adenocor, Aldurazyme, AllStar, Amaryl, Apidra, Arava, Aubagio, Augeoz, Brodactam, Cardace, Caspercid, Cerezyme, Cetapin, Clexane, Cordarone, Daonil, Depakote, Fabrazyme, Fasturtec, Fludara, Frisium, Insuman, Jevtana, Lantus, Lasilactone, Lasix, Lyxumia, Metosan, M-Nem, Myoril, Myozyme, Plavix, Primacor, Renvela Sachets, Soframycin, Solian, Stilnoct, Synvisc, Targocid, Taxotere, Telsite, Thymoglobuline, Thyrogen, Toujeo, Trental, Valparin, Vinlep, Zemiglo).

Vaccines (Adacel, Avaxim, FluQuadri, Hexaxim, Imovax Polio, Menactra, Pentaxim, Shan5, Shanchol, ShanIPV, ShanTT, Shanvac-B, Stamaril, Vaxigrip)

Consumer Healthcare products (Allegra, Allegra, Allegra M, Aminofit Forte, Amino-fit, Avil, Baralgan NU, Berrycran, Buscogast, Cetgel, Collaflex, Combiflam Plus, Combiflam Suspension, Combiflam IcyHotTM, Combiflam IcyHotTM spray, CoQ 300, DePURA by Sanofi, Dulcoflex Natural, DulcoSoft Sachet, E-Cod Plus, E-Cod W, Enlarge Forte, Enterogermina, Estoven XT, Festal N, FreeFlex Forte, Icegel, Lactacyd, Macraberin M, Mega FreeFlex, Multivite Gold, Multivite Woman, Multivite CD,
Multivite-FM Omega, Novalgin NU, Phospholip TF, Primosa, Radiance H, Seacod Active, Selace Forte,
Triomega)

Milestones

2013: Sanofi India launches Combiflam Plus.
2013: Sanofi ties up with IDF, PHFI to fight against diabetes among children in India.
2013: Sanofi India inks pact with Suzlon Energy for renewable energy.
2014: Sanofi India - Diabetic Teen from Pune achieves unique feat.
2014: Sanofi partners with Emcure Pharmaceuticals for marketing and distribution of its oncology portfolio in India.
2015: Sanofi delivers 4 lakh Shan5 vaccine doses to Gwalior and Jabalpur to support the immunization of children from five pediatric diseases.
2016: Sanofi India collaborates with National Institute of Pharmaceutical Education and Research (NIPER) Kolkata, to promote academic excellence and research.
2018: Sanofi receives positive CHMP opinion for dengue vaccine.
2018: Sanofi completes its acquisition of Ablynx following the expiration of the Squeeze-out Procedure.
2019: Sanofi signs strategic deal for exclusive US over-the-counter rights to Tamiflu in Flu Care.
2020: Sanofi Completes Acquisition of Synthorx, Inc.
2020: Sanofi joins forces with U.S. Department of Health and Human Services to advance a novel coronavirus vaccine.
2020: Sanofi and Translate Bio expand collaboration to develop mRNA vaccines across all infectious disease areas.